Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision cancer medicines, has announced inducement grants to seven new employees. The Compensation Committee approved nonstatutory stock options to purchase 82,950 shares of common stock under the company's 2023 Inducement Option Plan.

The stock options have an exercise price of $7.95 per share, matching the closing price on September 2, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.

News Market Reaction

+1.11%

1 alert

+1.11% News Effect

On the day this news was published, KURA gained 1.11%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on September 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 82,950 shares of common stock to seven (7) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $7.95 per share, the closing price of the Company’s common stock on September 2, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Contacts

Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

What inducement grants did Kura Oncology (KURA) announce in September 2025?

Kura Oncology announced nonstatutory stock options to purchase 82,950 shares of common stock granted to seven new employees, with an exercise price of $7.95 per share.

What is the vesting schedule for Kura Oncology's September 2025 inducement stock options?

The stock options vest over 4 years, with 25% vesting after one year and the remaining vesting monthly over 36 months, subject to continued employment.

What was the exercise price for KURA's September 2025 inducement stock options?

The exercise price was set at $7.95 per share, which was the closing price of Kura Oncology's common stock on September 2, 2025.

Under which plan were Kura Oncology's September 2025 inducement grants issued?

The inducement grants were issued under Kura Oncology's 2023 Inducement Option Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4).